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Background: The use of CoSealW, a polyethylene glycol sealant, in cardiac and vascular surgery for prevention of
anastomotic bleeding has been subject to prior investigations. We analysed our perioperative data to determine
the clinical benefit of using polyethylene glycol sealant to inhibit suture line bleeding in aortic surgery.
Methods: From January 2004 to June 2006, 124 patients underwent aortic surgical procedures such as full root
replacements, reconstruction and/or replacement of ascending aorta and aortic arch procedures. A Bentall
procedure was employed in 102 of these patients. In 48 of these, a polyethylene glycol sealant was added to the
anastomotic closure of the aortic procedure (sealant group) and the other 54 patients did not have this additive
treatment to the suture line (control group).
Results: There were no significant between-group differences in the demographic characteristics of the patients
undergoing Bentall procedures. Mean EuroSCORES (European System for Cardiac Operative Risk Evaluation) were
13.7 ± 7.7 (sealant group) and 14.4 ± 6.2 (control group), p = NS. The polyethylene glycol sealant group had reduced
intraoperative and postoperative transfusion requirements (red blood cells: 761 ± 863 versus 1248 ± 1206 ml, p = 0.02;
fresh frozen plasma: 413 ± 532 versus 779 ± 834 ml, p = 0.009); and less postoperative drainage loss (985 ± 972 versus
1709 ± 1302 ml, p = 0.002). A trend towards a lower rate of rethoracotomy was observed in the sealant group (1/48
versus 6/54, p = 0.07) and there was significantly less time spent in the intensive care unit or hospital (both p = 0.03).
Based on hypothesis-generating calculations, the resulting economic benefit conferred by shorter intensive care
unit and hospital stays, reduced transfusion requirements and a potentially lower rethoracotomy rate is estimated
at €1,943 per patient in this data analysis.
Conclusions: The use of this polymeric surgical sealant demonstrated improved intraoperative and postoperative
management of anastomotic bleeding in Bentall procedures, leading to reduced postoperative drainage loss, less
transfusion requirements, and a trend towards a lower rate of rethoracotomy. Hypothesis-generating calculations
indicate that the use of this sealant translates to cost savings. Further studies are warranted to investigate the
clinical and economic benefits of CoSeal in a prospective manner.
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Aortic repair and reconstruction (including aortic arch
surgery and combined procedures), despite being major
cardiac surgical procedures, are now commonplace.
Worldwide, tens of thousands of procedures are per-
formed each year for the treatment of aortic or thoracic
aneurysms, occlusions or dissections [1].
One of the main complications with these types of sur-
gical procedures is the intraoperative and postoperative
bleeding at the anastomotic suture line. The likelihood
of bleeding can be influenced by a range of factors in-
cluding comorbidities, surgical history, anticoagulation
therapies, the type of surgical procedure employed and
individual patient risk. This type of bleeding complica-
tion presents a major challenge to intraoperative and
postoperative haemostasis, and failure to achieve ad-
equate haemostasis can lead to a longer operative time,
a greater need for blood transfusion products and a
higher risk of postoperative complications and rethora-
cotomy. These factors and complications are obviously
detrimental to the patient and incur significant add-
itional costs. The level of additional costs is dependent
upon the need for rethoracotomies, length of stay in the
intensive care unit (ICU), overall duration of hospital
stay, and the additional use of medical equipment and
medical services used to diagnose and resolve the com-
plication. Considering the large number of procedures
performed each year, the maintenance of intraoperative
and postoperative haemostasis is essential not only for
improving patient outcomes, but also for the reduction
of these societal and healthcare costs.
Increasingly, surgical sealants such as polymeric poly-
ethylene glycol (PEG) are being utilised in cardiac and
vascular surgery to control anastamotic bleeding from
high-pressure suture lines [2-4]. In several clinical and
pre-clinical studies, PEG has been shown to provide
rapid and strong sealing while maintaining flexibility and
elasticity, and avoiding any disturbance of the wound
closure [5,6]. This PEG is a fully synthetic sealant con-
taining no human/animal proteins or gluteraldehyde and
it does not induce any adverse tissue responses, exhibits
minimal or no toxicity, and resorbs fully within four
weeks [3,5].
The objective of this retrospective patient case–control
analysis was to assess the effect on blood loss, transfu-
sion requirements, and associated cost savings when
adding a PEG sealant to the anastomotic closure of aor-
tic procedures performed using a Bentall procedure.
Methods
Patients and study setting
Between January 2004 and June 2006, 124 consecutive
patients underwent aortic-related surgical procedures in-
cluding full root replacements, reconstruction and/orreplacement of ascending aorta and aortic arch proce-
dures in the Cardiothoracic Surgery Department at the
Klinikum Oldenburg, Oldenburg, Germany. Patients
were operated on by any one of six cardiothoracic sur-
geons using standardised procedures, three of whom
routinely added a PEG sealant to the anastomotic clos-
ure of aortic procedures with the intent to enhance
sealing and reduce blood loss. Of the 124 patients, 102
underwent Bentall procedures and therefore comprised
a comparable cohort without procedures that may facili-
tate bleeding and thus influence between-group compar-
isons (e.g. deep hypothermic circulatory arrest). These
patients were retrospectively divided into two study
groups depending on the haemostatic procedure used by
the attending surgeon:
The sealant group i.e. those that received PEG as a
surgical sealant in addition to the suture line (standard
procedure plus PEG sealant performed by three of the
six surgeons). The control group i.e. those who did not
receive any additional treatment to the suture line
(standard procedure without the addition of a PEG seal-
ant which was performed by the other three of the six
surgeons).
Materials
The PEG sealant used in this study was CoSealW (Baxter
Healthcare Corporation, Deerfield, IL, USA), which is
composed of two synthetic PEGs, a dilute hydrogen chlor-
ide solution and a sodium phosphate/sodium carbonate
solution. It is indicated for use in vascular reconstructions
to achieve adjunctive haemostasis by mechanically sealing
areas of leakage. At the time of administration, the mixed
PEGs and solutions, which must be used within two hours
of reconstitution, generate a biocompatible, strongly ad-
herent hydrogel that forms a cohesive matrix on the tissue
within 60 seconds, and fully resorbs over the subsequent
weeks [7].
For patients in the sealant group, the PEG sealant was
sprayed in a prophylactic way on clamped vascular pros-
theses in a thin homogeneous layer over the anastomotic
sites; minimal volumes (2–4 ml) were applied to blotted or
air-dried surfaces and allowed to stand for at least one mi-
nute before unclamping. Application was in accordance
with the product instructions for use via a product-specific
gas-driven spray device (CoSeal Easy SprayW, Air Enhanced
Applicator, Baxter, Deerfield, IL, USA) [7]. Additional
movie files 1 and 2 show the intraoperative application of
PEG sealant in more detail (see additional file 1 and 2).
CoSeal was the only product used for aortic suture-line
sealing during the procedure (treatment group).
Operative procedure
Routine preoperative and intraoperative care protocols
were followed, and all patients were assessed prior to
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bin level and no hereditary coagulopathies. In elective
surgeries, preoperative aspirin was discontinued one
week prior to surgery. Patients only received blood sub-
stitution immediately prior to surgery in emergency cir-
cumstances. A drop in blood haemoglobin below the
normal levels (men: 13.5–17.5 g/dL; women: 12.0–
16.0 g/dL) was the trigger for intraoperative transfusion.
Aortic repair and reconstruction was carried out using a
Bentall procedure utilising a Medtronic FreestyleW stent-
less root prosthesis (Medtronic Inc. Minneapolis, MN).
In summary, once the diseased aortic tissue and valve
had been removed, proximal anastomosis was performed
using 20–25 single interrupted 4/0 EthibondW sutures in
a single plane. Mobilised coronary buttons were then
sewn end-to-side to the corresponding aortic sinus using
a continuous 5/0 polypropylene suture. Finally, the cra-
nial end of the bioprosthesis was sewn end-to-end to the
aorta with a continuous 4/0 polypropylene suture, com-
pleting the root replacement. Due to the short root pros-
thesis of the Medtronic FreestyleW device used for this
procedure, some patients required additional length,
which was provided by inserting a vascular tube graft
(VascutekW, Renfrewshire, Scotland). Any further sur-
gery was carried out according to standard procedures;
deaeration was performed following clamp removal and
protamine was administered upon cessation of bypass.
Outcomes
The evaluation of the effect of added PEG sealant was based
on the retrospective analysis of three key outcome measures:
1) requirement for transfusion based on volumes (ml)
of red blood cells (RBC) and fresh frozen plasma
(FFP) within the first 48 hours following surgery;
2) postoperative drainage volume (ml) within the first
48 hours following surgery; and
3) rate of rethoracotomy.
The same key measures were used to perform a
hypothesis-generating calculation of the costs associated
with the Bentall procedures employed, either with or with-
out PEG sealant. Indirect economic benefit was retro-
spectively estimated, with respect to reduced transfusion
requirements and rethoracotomy rate, based on the fol-
lowing typical costs at the Klinikum Oldenburg from
January 2004 to June 2006: RBC, €200 per unit; FFP, €160
per unit; PEG sealant, €237 per 2 ml application; ICU stay,
€400 per day; hospital stay, €150 per day; and rethoracot-
omy, €2000 per procedure (operative costs only).
Statistical analysis
Clinical assessment data were presented as mean± stand-
ard deviation (SD) and population characteristics as apercentage of each subgroup (treatment or control). The
following statistical tests were used to compare treatment
groups: Student’s t-tests (gender, age, weight, European
System for Cardiac Operative Risk Evaluation [Euro-
SCORE], cardiopulmonary bypass [CPB] time, aortic cross
clamp time, total operative duration [or time], drainage
volume, duration of ICU and total hospital stay),
Wilcoxon-Mann-Whitney tests (urgency of operation),
chi-square tests (surgical history and Bentall procedure),
or a two-proportion z-test (postoperative rethoracotomy).
P values of <0.05 were considered to be significant.
Results
Between January 2004 and June 2006, a total of 124 con-
secutive patients underwent aortic-related surgical pro-
cedures at the Department of Cardiothoracic Surgery,
Klinikum Oldenburg, Oldenburg, Germany. Of these,
102 patients underwent Bentall procedures and were
included in the analysis: 48 (47.1%) received PEG as a
surgical sealant in addition to the suture line (sealant
group) and 54 (52.9%) did not receive this additive treat-
ment to the suture line (control group). Demographic
profiles of the two patient groups were similar and
showed no significant differences between the sealant
and control groups (Table 1).
Compared with the control group, patients in the
sealant group required significantly fewer intraoperative
and postoperative transfusions of RBC (mean 761 ± 863
versus 1248 ± 1206 ml, p = 0.02; Table 1) or FFP
(413 ± 532 versus 779 ± 834 ml, p = 0.009). All other intra-
operative characteristics were similar between groups
(urgency, CPB time, aortic clamp time, total operative
duration, Table 1).
Postoperatively, drainage volumes were significantly
reduced in the sealant group (985 ± 972 ml) versus the
control group (1709 ± 1302 ml), p = 0.002 (Table 1), as
was the duration of ICU stay and the total hospital stay
(Table 1; both p = 0.03). In addition, a trend towards a
reduced rethoracotomy rate was observed in the sealant
group (1/48) versus the control group (6/54; p = 0.07).
No adverse events related to the use of PEG sealant were
reported during this study.
Overall, for the 102 procedures performed in this ana-
lysis, per patient cost-savings when adding a PEG sealant
to the suture line (sealant group) versus no additive
treatment (control group) for the anastomotic closure
during aortic surgery were estimated at €1,943 (Table 2).
Discussion
The results of this single centre, retrospective case series
demonstrate that adding a PEG sealant to the anasto-
motic closure of aortic Bentall procedures provides a
beneficial effect on blood loss and transfusion require-
ments. Compared with sutures alone, PEG sealant
Table 1 Demographic and perioperative characteristics of the study population
Bentall procedure PEG sealant (N = 48) Control (no sealant) (N= 54) p-value
Demographic characteristics
Gender (male) 31 37 NS
Age (years) 66.9 ± 9.5 70.3 ± 10.9 NS
Weight (kg) 82.6 ± 15.1 78.9 ± 13.9 NS
Surgical history (n,%) 6 (12.5) 6 (11.1) NS
Aortic-valve replacement 3 2 NS
CABG 3 4 NS
EuroSCORE 13.7 ± 7.7 14.4 ± 6.2 NS
Preoperative characteristics
Urgency of surgery (%)
Elective 42 (87.5) 46 (85.2) NS
Urgent 4 (8.3) 6 (11.1) NS
Emergent 2 (4.2) 2 (3.7) NS
Intraoperative characteristics
CPB time (min) 167.71 ± 64.24 155.94 ± 46.35 NS
Aortic clamp time (min) 109.71 ± 36.88 102.64 ± 26.52 NS
Total operative duration (min) 215.40 ± 69.35 231.78 ± 65.25 NS
Postoperative characteristics
Drainage volume (ml, within 48 hours) 985 ± 972 1709± 1302 0.002
(220–6500) (325–7500)
RBC (average per patient in ml) 761 ± 863 1248± 1206 0.02
FFP (average per patient in ml) 413 ± 532 779 ± 834 0.009
Rethoracotomy (n,%) 1 (2) 6 (11.1) 0.07
Due to diffuse bleeding 1 3
Due to hematoma 0 3
Duration of ICU stay (days) 4.2 ± 3.6 6.5 ± 6.3 0.03
Duration of total hospital stay (days) 16.2 ± 8.8 21.0 ± 12.2 0.03
PEG, polyethylene glycol; CABG, Coronary artery bypass graft; CPB, cardiopulmonary bypass; EuroSCORE, European System for Cardiac Operative Risk Evaluation;
SD, standard deviation.
P-values calculated using the following statistical tests: Student’s t-test, chi-square test, Wilcoxon-Mann-Whitney test, or Fisher’s exact test. All values are presented
as mean ± SD or percentages of subgroup populations.
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transfusion requirements, with no additional adverse
events. In addition, a trend towards a reduced rethora-
cotomy rate versus sutures alone was also observed.
These benefits may have translated into substantial costTable 2 Estimated per-patient cost savings when using PEG s
Surgical requirement Unit cost PEG sealan
RBC €200/unit 3.6 units (€7
FFP €160/unit 2.1 units (€3
PEG sealant €237/2 ml application 2 ml (€237)
Rethoracotomy* €2,000/procedure 0.02 (€41)
ICU stay (days) €400/day 4.3
Hospital stay (days) €150/day 16.1
Overall estimated cost saving per patient
RBC, red blood cells (1 unit = 250 ml); FFP, fresh frozen plasma (1 unit = 200 ml); PEG
*Operating room (OR)-associated costs only (i.e. anaesthesia, OR and staff time, but
Cost savings based on average reduced procedural requirements when using PEG s
2004 to June 2006.savings for aortic Bentall procedures over the 30-month
study period (January 2004 to June 2006).
Several studies have recommended the use of surgical
sealants for treating anastomotic suture lines in patients
undergoing aortic reconstructions [2-5,8], and the positiveealant for anastomotic closure during aortic surgery
t Control (no sealant) Cost saving using sealant
20) 5 units (€1,000) €280






, polyethylene glycol; ICU, intensive care unit.
excluding extended intensive care or hospital stay).
ealant using typical costs at the Klinikum Oldenburg in the period January
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ive analyses of sealant use in aortic reconstruction [9].
However, the case series reported here provides a more
accurate overview of routine clinical practice than a con-
trolled clinical study environment, and therefore the
results are highly relevant to practising cardiac surgeons.
In addition to the benefits on clinical outcomes
reported here, there are also important practical aspects
that should be considered. Unlike haemostatic gelatins
(with or without the use of thrombin), or haemostatic
agents that induce platelet aggregation, the PEG sealant
used in this study works independent of the clotting
cascade, allowing its use in patients with severely
inhibited coagulation. In addition, PEG sealant can and
should be applied pre-emptively of any bleeding and
requires the application of smaller volumes than other
sealants, particularly if the spray applicator is utilised.
This is advantageous as the use of smaller volumes of
sealant can help to reduce the risk of stenosis, which
is particularly important under the ostium of the left
coronary artery. While the PEG sealant used provides
a seal of great strength via covalent tissue bonds, it
still retains flexibility. This allows normal physiological
dilation without stiffening, thus avoiding any additional
wall stress and weakening of the surrounding tissue
[10]. The PEG sealant also begins to set in five sec-
onds and is fully polymerised as a hydrogel in one mi-
nute [5], providing rapid sealing of the prosthesis. This
prevents blood loss at unclamping, reducing the risk
of further complications related to the extracorporeal
circulation.
Cost calculations reported here are hypothesis gener-
ating, do not represent a detailed or formal analysis of
cost effectiveness and warrant further confirmation in
dedicated economic studies. Nevertheless, based on the
estimated €1,943 per patient cost saving associated
with use of PEG sealant in this analysis, it seems
plausible that substantial reductions observed for some
of the surgical requirements may have directly trans-
lated into procedural cost savings. The cost savings
associated with the lower rate of transfusions conferred
by the use of PEG sealant reported here add further to
the data supporting the economic benefit of this inter-
vention [11,12]. In particular, the suggested reduction
in the rethoracotomy rate, which in itself influences
the amount of RBC and FFP required as a result of
the complication, results in cost savings from the use
of PEG sealant far outweighing the cost of the treat-
ment itself. In addition, the significant reductions in
ICU stay and hospital stay associated with the use of
PEG sealant would be expected to further reduce
healthcare costs. We therefore consider the adjunctive
use of the PEG sealant in this analysis of considerable
economic benefit.As with all clinical studies, there are limitations that
should be considered. This was a retrospective analysis
of non-blinded data, recorded at a single study centre.
As such it may be open to potential bias. Three of the
participating surgeons routinely added a PEG sealant to
the anastomotic closure of aortic procedures, whereas
the other three did not. Therefore, the results may have
been influenced by particular surgeons’ experience and
individual techniques. Furthermore, the fact that the
data to be recorded for the efficacy and safety outcomes
were not pre-defined, but taken out of the existing rou-
tine documentation, may also impact the suitability of
the measured parameters. With regard to concomitant
aspirin use, while it is likely that urgent or emergent
cases did not have their aspirin discontinued before sur-
gery and postoperative drainage volumes were increased
as a result, the percentages of urgent/emergent cases
were similar in the two groups (6/48 [12.5%] versus 8/54
[14.8%], respectively). Postoperative hypertension was
not recorded during this study, so comparisons to estab-
lish the effectiveness of the PEG sealant in patients with
postoperative hypertension were not possible. While the
PEG sealant has been demonstrated to withstand supra-
physiological pressures of up to 660 ± 150 mmHg [6],
this is still an important clinical consideration that war-
rants further investigation in future studies.Conclusion
This retrospective analysis of aortic Bentall procedures
in 102 patients over a 30-month period assessed the ef-
fect on blood loss and transfusion requirements of add-
ing a PEG sealant to the anastomotic closure. The use of
PEG sealant for suture-line reinforcement provided sig-
nificant benefits on postoperative drainage and transfu-
sion requirements versus sutures alone, with a trend
towards a reduced rethoracotomy rate. These benefits
may also translate into considerable cost savings. The
clinically significant findings reported here warrant con-
firmation in prospective studies, which should also in-
clude the analysis of postoperative hypertension.Additional files
Additional file 1: Video 1. Intraoperative application of PEG sealant
during an aortic surgical procedure using a spray applicator.
Additional file 2: Video 2. Intraoperative application of PEG sealant
during an aortic surgical procedure using a tip applicator.Abbreviations
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